Sign in

    Dev Prasad • Lucid Capital Markets

    Dev Prasad, Ph.D., MBA, serves as Senior Vice President in equity research at Lucid Capital Markets, specializing in healthcare equities with a primary focus on inflammation and immunology. He covers small to mid-cap biotechnology companies, having recently initiated coverage on Opus Genetics, Avalo Therapeutics, iBio, and CalciMedica. Despite a challenging track record—ranking #3,918 out of 4,954 Wall Street analysts with a 50% success rate and an average return of -10.84%—he brings approximately four years of equity research experience from previous roles at Jefferies and JMP Securities, following product development positions at Sagent Pharmaceuticals, Fresenius, and Cubist Pharma. Dr. Prasad holds a Ph.D. and M.S. in Pharmaceutics and Drug Delivery from MCPHS, an MBA from Northwestern University’s Kellogg School of Management, and his role at Lucid Capital Markets is supported by credentials in both scientific and financial disciplines.

    Dev Prasad's questions to Palvella Therapeutics Inc (PVLA) leadership

    Dev Prasad's questions to Palvella Therapeutics Inc (PVLA) leadership • Q2 2025

    Question

    Dev Prasad of Lucid Capital Markets inquired about the anticipated clinical development timelines for the two new Qtorin programs and the company's approach to commercial manufacturing, including whether it would be in-house or with a CMO and any capacity planning.

    Answer

    CEO Wes Kaupinen and CSO Jeff Martini clarified that the new Qtorin rapamycin indication is closer to the clinic, while the new molecule program is expected to yield Phase II data in under 2.5 years for less than $10M. Wes Kaupinen confirmed the manufacturing strategy relies on multiple US-based third-party CDMOs for both the drug product and API, with capacity planning managed by their Head of CMC to ensure supply.

    Ask Fintool Equity Research AI